Education
About Us
Working with TipRanks
Follow Us
Bausch Health Companies (TSE:BHC)
TSX:BHC
BHC Stock Chart & Stats
C$9.25
-C$0.04(-0.35%)
At close: 4:00 PM EST
C$9.25
-C$0.04(-0.35%)
Day’s Range― - ―
52-Week RangeC$5.91 - C$13.74
Previous CloseN/A
Volume45.48K
Average Volume (3M)348.00K
Market Cap
C$3.53B
Enterprise ValueC$31.91B
Total Cash (Recent Filing)C$1.73B
Total Debt (Recent Filing)C$21.74B
Price to Earnings (P/E)7.1
Beta1.46
Next Earnings
Feb 25, 2026EPS Estimate
1.67Last Dividend Ex-Date
Aug 30, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)1.62
Shares Outstanding370,516,940
10 Day Avg. Volume265,825
30 Day Avg. Volume348,003
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$11.65Price Target Upside25.94% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Direct-to-Consumer CampaignXifaxan sales exceeded estimates, boosted by a successful direct-to-consumer campaign.
Profit GuidanceThe company's 2025 profit guidance has been raised, indicating optimism in future earnings.
Revenue GrowthBausch & Lomb sales were higher than anticipated, contributing to overall revenue growth.
Bears Say
Earnings PerformanceOperating income and EPS were below expectations due to higher SG&A spending and increased interest expenses.
Future ExpensesFavorable Q3 SG&A spending is not likely to recur, suggesting a potential increase in future expenses.
Interest ExpenseInterest expense was significantly higher than estimated due to refinancing debt at less favorable rates.
Bausch Health Companies News
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was C$5.91 and its highest was C$13.74 in the past 12 months.
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is C$3.53B.
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Feb 25, 2026 which is in 109 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Oct 29, 2025. The company reported C$1.62 earnings per share for the quarter, beating the consensus estimate of C$1.479 by C$0.141.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of C$0.097 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is 1.67.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 370,516,940 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of C$1.62 in its last earnings report, beating expectations of C$1.479. Following the earnings report the stock price went up 12.53%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Currently, no hedge funds are holding shares in TSE:BHC
Bausch Health Companies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
C$11.65 (25.94% Upside)
C$11.65 (25.94% Upside)
Insider Transactions
Bought Shares
Worth $333.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.91%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc. (BHC) is a global company focused on the development, manufacture, and marketing of a range of pharmaceutical and medical device products. The company operates primarily in the eye health, gastrointestinal, dermatology, and neurology sectors. Bausch Health's core product offerings include prescription medications, over-the-counter products, and medical devices, with a strong emphasis on innovative therapies and solutions for patients. The company also has a significant presence in the contact lens market through its Bausch + Lomb subsidiary, providing products that enhance vision and eye health.
BHC Company Deck
BHC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with multiple quarters of revenue and EBITDA growth, significant debt reduction, and strong product-level performance. However, some challenges remain in international markets and specific segments.View all TSE:BHC earnings summariesBHC Revenue Breakdown
47.34% Bausch + Lomb
25.69% Salix
12.23% International
10.77% Diversified Products
3.96% Solta Medical
BHC Stock 12 Month Forecast
Average Price Target
C$11.65
▲(25.94% Upside)
Technical Analysis
Theratechnologies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Cronos Group
―
HLS Therapeutics Inc
―
Options Prices
Currently, No data available
---